Iron sucrose

Generic Name: Iron sucrose

Brand Names: Velphoro, Venofer

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₂₉Fe_₅Na_₂O_₂₃

CAS Number: 8047-67-4

Unique Ingredient Identifier: FZ7NYF5N8L

Background: Iron sucrose (sucroferric oxyhydroxide or iron saccharate) is used as a source of iron in patients with iron deficiency anemia with chronic kidney disease (CKD), including those who are undergoing dialysis (hemodialysis or peritoneal) and those who do not require dialysis. Due to less side effects than iron dextran, iron sucrose is more preferred in chronic kidney disease patients.

Indication: Iron sucrose is elemental iron as an injection. It replenishes body iron stores in patients with iron deficiency.

Associated Conditions: Hyperphosphataemia

Clinical Trials

Safety and Tolerability of 200mg and 100mg of Venofer Administered to Hemodialysis(HD) Patients

Phase 4

Completed

Conditions: Hemodialysis

Interventions: Drug: Venofer® 200 mg
Drug: Venofer® 100 mg

First Posted Date: 2024-11-15

Last Posted Date: 2024-11-15

Lead Sponsor: American Regent, Inc.

Target Recruit Count: 400

Registration Number: NCT06690450

Intravenous Iron Versus Oral Iron for the Treatment of Iron Deficiency Anemia

Phase 3

Recruiting

Conditions: Iron Deficiency Anemia of Pregnancy

Interventions: Drug: Venofer 200 MG Per 10 ML Injection
Drug: Ferrous sulfate

First Posted Date: 2024-04-16

Last Posted Date: 2024-04-16

Lead Sponsor: Arrowhead Regional Medical Center

Target Recruit Count: 900

Registration Number: NCT06366698

Locations: 🇺🇸
Arrowhead Regional Medical Center, Colton, California, United States

Comparison Between Outcomes of Pregnant Women Treated With Ferinject vs. Venofer for Iron Deficiency Anemia

Phase 4

Not yet recruiting

Conditions: Pregnancy Anemia
Anemia, Iron Deficiency

Interventions: Drug: Venofer 200 MG Per 10 ML Injection
Drug: Ferinject

First Posted Date: 2023-09-29

Last Posted Date: 2023-10-06

Lead Sponsor: Western Galilee Hospital-Nahariya

Target Recruit Count: 200

Registration Number: NCT06061393

Iron Replacement to Reduce Anemia During Neoadjuvant Chemotherapy

Phase 2

Recruiting

Conditions: Anemia

Interventions: Drug: Venofer

First Posted Date: 2023-04-05

Last Posted Date: 2025-03-11

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 34

Registration Number: NCT05800600

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Bioequivalence Study Assessing Iron Sucrose or Venofer® in Healthy Adult Subjects

Phase 1

Completed

Conditions: Bioequivalance

Interventions: Drug: Iron Sucrose Injection
Drug: Venofer Injection

First Posted Date: 2019-11-07

Last Posted Date: 2020-07-31

Lead Sponsor: Baxter Healthcare Corporation

Target Recruit Count: 196

Registration Number: NCT04155814

Locations: 🇺🇸
Baxter Investigational Site, Miami, Florida, United States

PA21 Safety and Efficacy in Adult Chinese Subjects

Phase 3

Completed

Conditions: Chronic Kidney Disease Requiring Chronic Dialysis
Hyperphosphatemia

Interventions: Drug: PA21
Drug: sevelamer carbonate

First Posted Date: 2018-08-23

Last Posted Date: 2021-06-02

Lead Sponsor: Vifor Fresenius Medical Care Renal Pharma

Target Recruit Count: 286

Registration Number: NCT03644264

Locations: 🇨🇳
Southern Medical University Nanfang Hospital, Guangzhou, Guangdong, China

Velphoro and Impact on the Oral Cavity and Gut Microbiome

Terminated

Conditions: Hyperphosphatemia

Interventions: Drug: Velphoro
Other: saliva collection
Other: Supragingival biofilm collection
Other: stool collection
Other: blood collection

First Posted Date: 2018-01-24

Last Posted Date: 2020-11-25

Lead Sponsor: RWTH Aachen University

Target Recruit Count: 22

Registration Number: NCT03409757

Locations: 🇩🇪
University Hospital of RWTH Aachen, Department of Medicine II, Aachen, Germany

Bioequivalence Study Comparing Single Dose of Ferrinemia® Injection With a Single Dose of Venofer® Injection in Healthy Male Volunteers

Phase 1

Completed

Conditions: Heathy Volunteers

Interventions: Drug: Venofer
Drug: Ferrinemia

First Posted Date: 2017-03-28

Last Posted Date: 2018-07-05

Lead Sponsor: Azad Pharma AG

Target Recruit Count: 48

Registration Number: NCT03093883

Locations: 🇦🇹
Medical University of Vienna, Vienna, Austria

Efficacy Study of Intravenous Iron Preparation to Iron Deficiency Anemia

Phase 3

Completed

Conditions: Iron Deficiency Anemia

Interventions: Drug: Z-213
Drug: Saccharated Ferric Oxide

First Posted Date: 2016-04-07

Last Posted Date: 2018-03-06

Lead Sponsor: Zeria Pharmaceutical

Target Recruit Count: 238

Registration Number: NCT02731534

Non-interventional Study to Investigate the Short and Long Term Real-life Safety, Effectiveness, and Adherence of Velphoro® in Patients With Hyperphosphataemia Undergoing Haemodialysis (HD) or Peritoneal Dialysis (PD)

Completed

Conditions: Hyperphosphatemia

Interventions: Drug: sucroferric oxyhydroxide

First Posted Date: 2016-02-22

Last Posted Date: 2019-10-01

Lead Sponsor: Vifor Fresenius Medical Care Renal Pharma

Target Recruit Count: 1400

Registration Number: NCT02687594

Locations: 🇫🇷
Centre Hospitalier LYON-SUD, Pierre Benite, France
🇩🇪
Klinikum Coburg, Coburg, Germany
🇬🇧
Salford Royal Hospitals NHS Trust, Manchester, United Kingdom

and more 4 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy